<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CSBJ2004 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 pdf ?>
<?FILEmmc2 xlsx ?>
<?FILEmmc3 xlsx ?>
<?FILEmmc4 xlsx ?>
<?FILEmmc5 xlsx ?>
<?FILEmmc6 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id>
    <journal-title-group>
      <journal-title>Computational and Structural Biotechnology Journal</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2001-0370</issn>
    <publisher>
      <publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9882952</article-id>
    <article-id pub-id-type="pii">S2001-0370(23)00037-5</article-id>
    <article-id pub-id-type="doi">10.1016/j.csbj.2023.01.038</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CoV2-TCR: A web server for screening TCR CDR3 from TCR immune repertoire of COVID-19 patients and their recognized SARS-CoV-2 epitopes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au0005">
        <name>
          <surname>Jian</surname>
          <given-names>Xingxing</given-names>
        </name>
        <email>jianxingxing@foxmail.com</email>
        <xref rid="aff0005" ref-type="aff">a</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au0010">
        <name>
          <surname>Zhang</surname>
          <given-names>Yu</given-names>
        </name>
        <xref rid="aff0010" ref-type="aff">b</xref>
        <xref rid="aff0015" ref-type="aff">c</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au0015">
        <name>
          <surname>Zhao</surname>
          <given-names>Jingjing</given-names>
        </name>
        <xref rid="aff0010" ref-type="aff">b</xref>
        <xref rid="aff0020" ref-type="aff">d</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au0020">
        <name>
          <surname>Zhao</surname>
          <given-names>Zhuoming</given-names>
        </name>
        <xref rid="aff0010" ref-type="aff">b</xref>
        <xref rid="aff0020" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author" id="au0025">
        <name>
          <surname>Lu</surname>
          <given-names>Manman</given-names>
        </name>
        <xref rid="aff0010" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au0030">
        <name>
          <surname>Xie</surname>
          <given-names>Lu</given-names>
        </name>
        <email>xielu@sibpt.com</email>
        <xref rid="aff0005" ref-type="aff">a</xref>
        <xref rid="aff0010" ref-type="aff">b</xref>
        <xref rid="cor2" ref-type="corresp">⁎⁎</xref>
      </contrib>
      <aff id="aff0005"><label>a</label>Bioinformatics Center &amp; National Clinical Research Centre for Geriatric Disorders &amp; Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China</aff>
      <aff id="aff0010"><label>b</label>Shanghai-MOST Key Laboratory of Health and Disease Genomics (Chinese National Human Genome Center at Shanghai), Institute of Genome and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China</aff>
      <aff id="aff0015"><label>c</label>School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China</aff>
      <aff id="aff0020"><label>d</label>College of Food Science and Technology, Shanghai Ocean University, Shanghai, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding author. <email>jianxingxing@foxmail.com</email></corresp>
      <corresp id="cor2"><label>⁎⁎</label>Corresponding author at: Bioinformatics Center &amp; National Clinical Research Centre for Geriatric Disorders &amp; Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China. <email>xielu@sibpt.com</email></corresp>
      <fn id="fn1">
        <label>1</label>
        <p id="ntp0005">These authors equally contributed to this study.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>27</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <volume>21</volume>
    <fpage>1362</fpage>
    <lpage>1371</lpage>
    <history>
      <date date-type="received">
        <day>25</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>8</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>26</day>
        <month>1</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab0010">
      <p>Although multiple vaccines have been developed and widely administered, several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have been reported to evade immune responses and spread diffusely. Here, 108 RNA-seq files from coronavirus disease 2019 (COVID-19) patients and healthy donors (HD) were downloaded to extract their TCR immune repertoire by MiXCR. Those extracted TCR repertoire were compared and it was found that disease progression was related negatively with diversity and positively with clonality. Specifically, greater proportions of high-abundance clonotypes were observed in active and severe COVID-19 samples, probably resulting from strong stimulation of SARS-CoV-2 epitopes and a continued immune response in host. To investigate the specific recognition between TCR CDR3 and SARS-CoV-2 epitopes, we constructed an accurate classifier CoV2-TCR with an AUC of 0.967 in an independent dataset, which outperformed several similar tools. Based on this model, we observed a huge range in the number of those TCR CDR3 recognizing those different peptides, including 28 MHC-I epitopes from SARS-CoV-2 and 22 immunogenic peptides from SARS-CoV-2 variants. Interestingly, their proportions of high-abundance, low-abundance and rare clonotypes were close for each peptide. To expand the potential application of this model, we established the webserver, CoV2-TCR, in which users can obtain those recognizing CDR3 sequences from the TCR repertoire of COVID-19 patients based on the 9-mer peptides containing mutation site(s) on the four main proteins of SARS-CoV-2 variants. Overall, this study provides preliminary screening for candidate antigen epitopes and the TCR CDR3 that recognizes them, and should be helpful for vaccine design on SARS-CoV-2 variants.</p>
    </abstract>
    <abstract abstract-type="graphical" id="ab0015">
      <title>Graphical Abstract</title>
      <p>
        <fig id="fig0020" position="anchor">
          <alt-text id="at0030">ga1</alt-text>
          <graphic xlink:href="ga1"/>
        </fig>
      </p>
    </abstract>
    <kwd-group id="keys0005">
      <title>Keywords</title>
      <kwd>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</kwd>
      <kwd>Coronavirus disease 2019 (COVID-19)</kwd>
      <kwd>T cell receptor (TCR)</kwd>
      <kwd>Complementary determining regions 3 (CDR3)</kwd>
      <kwd>Antigen epitope</kwd>
      <kwd>Immunogenic peptide</kwd>
      <kwd>CoV2-TCR</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="sec0005">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0005">Since late 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly evolved into a pandemic disease, officially named coronavirus disease 2019 (COVID-19) by the World Health Organization. To date, it has been broken out in more than 200 countries or regions worldwide, resulting in more than 534.5 million confirmed cases and more than 6.3 million deaths (Accessed on 16 June 2022, https://covid19.who.int). Critically, although multiple vaccines have been developed and widely administered, several SARS-CoV-2 variants derived from mutations in the major histocompatibility complex class I (MHC-I)-restricted epitopes have been reported to evade immune response <xref rid="bib1" ref-type="bibr">[1]</xref>. Wang et al. investigated the susceptibility to immune evasion of the SARS-CoV-2-specific antibody in COVID-19 convalescents for the 2 years following discharge and showed that Omicron variants largely escaped any preexisting immunity in recovered individuals <xref rid="bib2" ref-type="bibr">[2]</xref>. In addition, developing new and effective vaccine was recommended as a strategy to limit transmission of Omicron and emerging variants <xref rid="bib3" ref-type="bibr">[3]</xref>.</p>
    <p id="p0010">As with any viral infection, pathogen-derived antigens peptides (8–11-mer) are presented together with MHC-I (HLA-I in human) molecules on the surface of infected cells <xref rid="bib4" ref-type="bibr">[4]</xref>. Then, the exhibited peptide-MHC complex (pMHC) is specifically recognized by CD8 + T cells <italic>via</italic> T cell receptors (TCRs), leading to the eradication of infected cells, where naive T cells are induced for clonal expansion of various subsets with identical TCRs <xref rid="bib5" ref-type="bibr">[5]</xref>. In addition, TCRs on circulating T cells are mostly heterodimers with alpha (α) and beta (β) subunits, and the hypervariable TCR repertoire mainly results from the highly diverse complementary determining regions (CDRs) shaped by VDJ genes recombination localized in the TCR α and β chains <xref rid="bib6" ref-type="bibr">[6]</xref>. Notably, the third CDR (CDR3) in the TCR β chain is responsible for the recognition of the antigen peptide in pMHC. Thus, those diverse CDR3 in the TCRβ repertoire of COVID-19 patients play a key role in the clearance of SARS-CoV-2.</p>
    <p id="p0015">Reportedly, SARS-CoV-2 infection activates the host’s adaptive immune system against virus, including both antibody immunity produced by B cells and T cell immunity delivered by CD4<sup>+</sup> T cells as the helper T cells with CD8<sup>+</sup> T cells as the cytotoxic cells <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>. Therein, neutralizing antibodies can prevent the binding and entry of virus. As a supplement to antibodies, CD8<sup>+</sup> T cells prevent effectively the establishment of infection by clearing the infected cells after exposure <xref rid="bib11" ref-type="bibr">[11]</xref>, especially tissue-resident memory T cells <xref rid="bib12" ref-type="bibr">[12]</xref>. Grau-Expósito et al <xref rid="bib13" ref-type="bibr">[13]</xref>. showed the response of peripheral and lung resident memory T cell against SARS-CoV-2 during acute infection. Moreover, the clinical data from severe COVID-19 patients showed that the CD8<sup>+</sup> T cells were significantly higher in those surviving patients <xref rid="bib14" ref-type="bibr">[14]</xref>. A higher proportion of SARS-CoV-2 specific CD8<sup>+</sup> T cells were observed in mild cases and these CD8<sup>+</sup> T cells have extensive and strong memory after the recovery period of COVID-19 <xref rid="bib15" ref-type="bibr">[15]</xref>. Terminally differentiated CD8<sup>+</sup> GZMB<sup>+</sup> effector cells were clonally expanded both during and after the infection, whereas CD8<sup>+</sup> GZMK<sup>+</sup> lymphocytes were further expanded after infection and represented bona fide memory precursor effector cells <xref rid="bib16" ref-type="bibr">[16]</xref>. Thus, the anti-SARS-CoV-2 T-cell-mediated immune response could be crucial for immune memory against SARS-CoV-2 infection.</p>
    <p id="p0020">In addition, there is evidence that the SARS-CoV-2 specific T cells were found in both COVID-19 patients and unexposed healthy donors <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>. This suggests that memory T cells recognizing the SARS-CoV-2 variants may have already existed in human beings. These existing memory T cells may result from previous cross-reactivity of T cells primed by seasonal coronaviruses, such as SARS or influenza <xref rid="bib17" ref-type="bibr">[17]</xref>. Therefore, we hypothesized, in TCR repertoire of COVID-19 patients, there existed TCR CDR3 sequences that can recognize specific epitopes from any SARS-CoV-2 variants.</p>
    <p id="p0025">Previously, we have constructed a prediction tool of immunogenic neoantigens, namely DeepCNN-Ineo, aimed at screening those tumor neoantigens bound by HLA molecular and recognized by TCR sequences <xref rid="bib19" ref-type="bibr">[19]</xref>. In this study, we obtained 108 RNA-seq files of peripheral blood, including 69 samples from COVID-19 patients and 39 samples from HD, to extract their TCRβ immune repertoire, which was found to correlate with the disease progression of COVID-19 samples. Furthermore, an accurate model configured in an easy-to-use web server, called CoV2-TCR, was constructed and implemented to investigate those TCR CDR3 recognizing epitopes from SARS-CoV-2 or its variants. As a result, those epitopes recognized by most TCR CDR3 sequences may be selected as candidate antigen peptides for vaccine design, while the number of these recognizing CDR3 sequences may reflect, to some extent, the protective coverage of the vaccine.</p>
  </sec>
  <sec id="sec0010">
    <label>2</label>
    <title>Materials and methods</title>
    <sec id="sec0015">
      <label>2.1</label>
      <title>Samples and data collection</title>
      <p id="p0030">In this study, 108 RNA-seq files of peripheral blood samples were downloaded from European Nucleotide Archive database with the search ID PRJEB38339, including 69 COVID-19 samples from 37 SARS-CoV-2 infected patients and 39 samples from 19 healthy donors (HD). Referring to a previous study on PRJEB38339 <xref rid="bib20" ref-type="bibr">[20]</xref>, the 69 COVID-19 samples can be divided into active and recovered groups according to the disease progression and further assigned into asymptomatic, mild, moderate, severe, and fatal groups according to the severity observed in patients. Of note, as described in the data source publication <xref rid="bib20" ref-type="bibr">[20]</xref>, the severity categories 'asymptomatic' and 'mild' are almost entirely included within the disease progression category 'recovered', while the 'moderate', 'severe' and 'fatal' are almost entirely included within the 'active' disease group.</p>
    </sec>
    <sec id="sec0020">
      <label>2.2</label>
      <title>Extraction and analysis of TCR immune repertoire</title>
      <p id="p0035">Based on the RNA-seq files (fastq) obtained from all samples, MiXCR software (copyright 2018, MiLaboratory, LLC Revision 225a025b) was used to extract TCR immune repertoire of each sample <xref rid="bib21" ref-type="bibr">[21]</xref>, in which those columns include cloneID, cloneCount, cloneFraction, allVHitsWithScore, allDHitsWithScorec, allJHitsWithScorec, nSeqCDR3, aaSeqCDR3 and <italic>etc.</italic> Since the CDR3 in the TCRβ chain is responsible for the recognition of the antigen peptide in pMHC, only TCRβ CDR3 (TRB) was utilized. That is, the unique TCRβ CDR3 sequences were treated as clonotypes in this study. On the R (version 4.1.2) platform, R package immunarch (version 0.6.7) were applied for analysis of TCR immune repertoire, including diversity, clonotype distribution and tracking.</p>
    </sec>
    <sec id="sec0025">
      <label>2.3</label>
      <title>Construction of deep learning convolution neural network model</title>
      <p id="p0040">We constructed a deep learning convolution neural network model to explore the specific recognition pairs between TCR CDR3 sequences and SARS-CoV-2 epitopes (<xref rid="sec0095" ref-type="sec">Fig. S1</xref>). The pairs between SARS-CoV-2 antigen epitopes and TCR CDR3 amino-acid sequences were first encoded into a feature matrix by using one-hot encoding. Here, we focused on those HLA-I antigens epitopes and TCR CDR3 sequences with the length of (8−11)-mer and (∼25)-mer, respectively. Thus, the paired epitope-CDR3 sequences were encoded and zero-padded as a matrix with dimension of 36<inline-formula><mml:math id="M1" altimg="si0001.svg"><mml:mo>×</mml:mo></mml:math></inline-formula>20.</p>
      <p id="p0045">The epitope-CDR3 pairs were encoded to obtain the feature matrix, and two 1D convolutional layers were applied. Specifically, one layer with 32 filters and another with 64, was followed by a batch normalization layer with momentum of 0.99. Next, a max pooling layer with pooling kernel size of 2 was applied, aiming to reduce the feature dimension and avoid overfitting. There were three fully connected layers with 128, 64 and 32 variables following the flattened layer. Each of the fully connected layers had the rectified linear unit (ReLU) activation function. Subsequently, before the last output layer, a dropout layer with probabilities of 0.3 was added for randomly discarding variables in the hidden layer. Eventually, an output layer with two variables and the Softmax activation function was adopted to represent the final statistical classification score, which was used to judge the specific recognition of peptides by TCR CDR3. Here, we regarded the predictive score of more than 0.95 to be valid recognition.</p>
      <p id="p0050">An adagrad optimizer with a learning rate of 0.005 was used to automatically decay learning rate by using the number of iterations and accumulated gradients. MSE was chosen as the objective function. The neural network was trained for 100 epochs and the batch size was set to 20.</p>
      <p id="p0055">We constructed and trained this model using TensorFlow 1.14.0 and Python (3.7.6) packages Numpy (version 1.19.5), Pandas (version 0.25.3), Biopython (version 1.76), scikit-learn (version 0.24.2), and scipy (version 1.4.1).</p>
    </sec>
    <sec id="sec0030">
      <label>2.4</label>
      <title>The datasets for model construction and validation</title>
      <p id="p0060">We first searched those recognized pairs between SARS-CoV-2 epitopes and TCR CDR3 sequences in IEDB <xref rid="bib22" ref-type="bibr">[22]</xref> and VDJdb <xref rid="bib23" ref-type="bibr">[23]</xref>. And, 11,388 and 381 recognized pairs were downloaded from IEDB and VDJdb, respectively. These recognized pairs have been verified experimentally, and were therefore regarded as positive pairs for model construction and validation.</p>
      <p id="p0065">In addition, in IEDB and TCRdb <xref rid="bib24" ref-type="bibr">[24]</xref>, we also obtained 22,805 TCR CDR3 sequences derived from seven types of tumors, <italic>i.e.</italic> breast cancer, colorectal cancer, gastric cancer, glioblastoma, lung cancer, melanoma, ovarian cancer. In IEDB, we also downloaded 50,639 recognized pairs between EBV epitopes and TCR CDR3 sequences, and 408 recognized pairs between HIV epitopes and TCR CDR3 sequences. Additionally, 1313 TCR CDR3 sequences derived from healthy people were obtained as well. We hypothesized that these TCR CDR3 sequences completely unrelated to SARS-CoV-2 epitopes should not specifically recognize SARS-CoV-2 epitopes. In order to construct negative pairs, these TCR CDR3 non-induced from SARS-CoV-2 epitopes were randomly paired with those SARS-CoV-2 epitopes from the positive set above.</p>
      <p id="p0070">We first merged the positive pairs downloaded from IEDB and negative pairs derived from tumors and EBV, and then removed duplicated pairs and those pairs containing unusual amino acids (<italic>e.g.</italic> B, J, O, U, X, Z). Further, we only retained those pairs involving (8−11)-mer epitopes and (∼25)-mer CDR3. In total, 50,949 pairs were obtained for model construction, including 11,056 positive pairs and 39,893 negative pairs. Subsequently, with the ratio of 8:2, these pairs were randomly divided into training dataset (40,759 pairs) and test dataset (10,190 pairs).</p>
      <p id="p0075">Similarly, we also merged an independent validation dataset for model validation, including those positive pairs downloaded from TCRdb and those negative pairs derived from HIV and healthy people. After carrying out the same filtration and selection as above, our validation dataset totally contained 880 pairs, including 334 positive pairs and 546 negative pairs.</p>
    </sec>
    <sec id="sec0035">
      <label>2.5</label>
      <title>Screening of immunogenic peptides in SARS-CoV-2 variants</title>
      <p id="p0080">In 2019nCoVR (https://ngdc.cncb.ac.cn/ncov/knowledge/compare) <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, we obtained those amino-acid mutations exhibiting a frequency of greater than 0.7 in the four main proteins of the seven SARS-CoV-2 variants, <italic>i.e.</italic> alpha, beta, delta, gamma, lambda, mu, omicron, respectively. Then, based on those mutation sites and the reference amino-acid sequences of the four main proteins in SARS-CoV-2, the (8−11)-mer peptides containing mutation site(s) were extracted for subsequent immunogenicity prediction. Meanwhile, netMHCpan 4.1 EL <xref rid="bib29" ref-type="bibr">[29]</xref> and IEDB Analysis Resource (Class I Immunogenicity) <xref rid="bib22" ref-type="bibr">[22]</xref> were respectively applied, in which the 12 HLA types with high proportion in the world were used, namely HLA-A* 01:01, HLA-A* 02:01, HLA-A* 03:01, HLA-A* 11:01, HLA-A* 23:01, HLA-A* 24:02, HLA-B* 07:02, HLA-B* 08:01, HLA-B* 35:01, HLA-B* 40:01, HLA-B* 44:02, HLA-B* 44:03. Those peptides with %rank of less than 0.5 and IEDB immunogenicity score of greater than 0.15 were considered as strong immunogenicity. And, we screened 22 predicted immunogenic peptides (<xref rid="tbl0010" ref-type="table">Table 2</xref>).</p>
    </sec>
    <sec id="sec0040">
      <label>2.6</label>
      <title>Establishment of online web tool</title>
      <p id="p0085">Based on the model CoV2-TCR constructed above, we established a user-friendly web server. This tool required users to select a specific protein from SARS-CoV-2, <italic>i.e.</italic> spike glycoprotein (S), membrane protein (M), envelop protein (E), or nucleocapsid protein (N), and its specified mutation amino-acid site. After submitting, users would be provided with those TCR CDR3 sequences that can recognize the related mutant peptides.</p>
      <p id="p0090">To implement an interaction interface and improve user experience, the front-end web framework was built by Vue.js and Element-UI, and the back-end was realized by Flask.</p>
    </sec>
  </sec>
  <sec id="sec0045">
    <label>3</label>
    <title>Results</title>
    <sec id="sec0050">
      <label>3.1</label>
      <title>Comparison of diversity, richness and clonality of the TCR immune repertoire</title>
      <p id="p0095">In this study, 108 RNA-seq files of peripheral blood, including 69 COVID-19 samples and 39 HD samples, were individually used to extract TCR immune repertoire. Subsequently, for each sample, the Chao1 index and Shannon index were separately evaluated to measure the richness and diversity of TCR immune repertoire. Here, the general richness and diversity in COVID-19 samples were observed with no significant difference compared to that in HC (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>a, d). However, when dividing those COVID-19 samples into active and recovered groups according to the disease progression, the richness and diversity of those active samples were significantly lower, while those recovered patients were significantly higher values (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>b, e). Further, according to the disease severity observed in the COVID-19 patients, a significant decrease in richness and diversity was observed in mild, moderate, and severe groups respectively (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>c, f). Meanwhile, we observed that those mild samples presented higher richness and diversity than those of HD, and no significant difference between those of severe and fatal samples. Thus, we considered that the richness and diversity of TCR immune repertoire in COVID-19 patients could be used to negatively indicate the disease progression and severity degree. Noteworthy, as described in the Method, the severity categories 'asymptomatic' and 'mild' are almost entirely included within the disease progression category 'recovered', while the 'moderate', 'severe' and 'fatal' are almost entirely included within the 'active' disease group.<fig id="fig0005"><label>Fig. 1</label><caption><p>Comparison of TCR immune repertoire. a, d, g) Comparison of Chao1 (a), Shannon (d), and Clonality (g) between HD and COVID-19 samples. b, e, h) Comparison of Chao1 (b), Shannon (e), and Clonality (h) between HD, active COVID-19 samples, and recovered COVID-19 samples. c, f, i) Comparison of Chao1 (c), Shannon (f), and Clonality (i) between HD and COVID-19 samples in different severity degree.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p>
      <p id="p0100">In addition, the clonality from each sample was separately estimated as well. As expected, there was a significant increase in clonality in COVID-19 samples due to the SARS-CoV-2 infection (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>g). In particular, those active patients showed a remarkably higher clonality compared to that in HC, while those recovered patients presented a significantly lower clonality (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>h). Consistently, we observed that a significantly increased clonality was detected in those patients with mild, moderate, and severe COVID-19 samples respectively (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>i), suggesting that the clonality of TCR immune repertoire could be used to positively indicate the disease progression and severity degree. Taken together, SARS-CoV-2 infection resulted in clonal expansion in TCR immune repertoire of COVID-19 patients, which is positively correlated with the disease severity of the patients.</p>
    </sec>
    <sec id="sec0055">
      <label>3.2</label>
      <title>Investigation of clonotypes in patients with COVID-19 infection</title>
      <p id="p0105">The immune system is central to maintaining the body in a healthy state by detecting and evicting those constantly exposed threats, including various pathogens and cancer cells. In general, the recognition of antigens by T cells activates their proliferation and/or phenotypic changes, leading to alteration of TCR repertoire <xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>. Here, a total of 209,428 and 398,033 unique clonotypes was respectively detected in HD and COVID-19 samples, of which 17,728 clonotypes were shared (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>a). Comparatively, those unshared clonotypes from COVID-19 samples (380,305) were hypothesized to be driven and produced by SARS-CoV-2 epitopes. Therefore, when assigning those COVID-19 samples into active and recovered groups according to disease progression, we found that fewer unshared clonotypes were obtained from those active samples than those from recovered samples (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>b). Similarly, fewer unshared clonotypes were obtained from those fatal/severe samples than from those mild/moderate samples (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>c). These observations were consistent with the low diversity in active samples and in severe/fatal samples described above, resulting from the strong stimulus of SARS-CoV-2 epitopes.<fig id="fig0010"><label>Fig. 2</label><caption><p>Investigation of TCR immune repertoire. a, d, e) Venn (a), clonotypes distribution (d), and clone degree (e) of TCR repertoire between HD and COVID-19 samples. b, f, g) Venn (b), clonotypes distribution (f), and clone degree (g) of TCR repertoire between HD, active COVID-19 samples, and recovered COVID-19 samples. c, h, i) Venn (c), clonotypes distribution (h), and clone degree (i) of TCR repertoire between HD and COVID-19 samples in different severity degree. (j) Clone tracking of top 20 high-abundance clonotypes in COVID-19 patients with the different disease progression. (k) Clone tracking of top 20 high-abundance clonotypes in COVID-19 patients with the different severity degree.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p>
      <p id="p0110">Next, to investigate those biased clonotypes derived from SARS-CoV-2 infection in COVID-19 samples, the distribution between the number of clonotypes and the number of cells per clonotype was further analyzed. As shown in <xref rid="fig0010" ref-type="fig">Fig. 2</xref>d, the number of clonotypes decreased gradually with the increase of the number of cells characterized by a certain clonotype in the immune repertoire. That is to say, as a result of continued stimulation by SARS-CoV-2 antigens, more characteristic clonotypes were observed to appear in COVID-19 samples. To compare them, we characterized those clonotypes with the number of T cells (<italic>i.e.</italic> abundance) less than <italic>2</italic><sup><italic>1</italic></sup>, less than <italic>2</italic><sup><italic>5</italic></sup>, and greater than <italic>2</italic><sup><italic>5</italic></sup> as rare, low-abundance, and high-abundance, respectively. Those high-abundance clonotypes were considered to result from the strong stimulus from SARS-CoV-2 antigens. Therein, high-abundance clonotypes accounted for 4.42% of the total in HD samples, while a higher proportion (8.75%) was detected in COVID-19 samples (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>e). Consistently, the higher proportion of high-abundance clonotypes was found in active patients than that in recovered patients (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>f, g), and the higher proportion of high-abundance T cells was found in fatal/severe samples than that in mild/moderate samples (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>h, i). These observations echoed the fewer clonotypes in active samples and in severe/fatal samples, also resulting from host’s immune response to SARS-CoV-2 epitopes.</p>
      <p id="p0115">In addition, we further focused on those 380,305 unique clonotypes unshared with 39 HD samples, in which the number of high-abundance, low-abundance, and rare clonotypes was 37,562, 236,182, and 106,561, respectively. Then, the top 20 high-abundance clonotypes were singled out for subsequent clonotype tracking. As shown in <xref rid="fig0010" ref-type="fig">Fig. 2</xref>j, k, we tracked their proportions at each group, illustrating their changes in immune repertoire of the COVID-19 samples at different infected periods. Consistent with the observation above, the sum proportion of recovered samples and mild/moderate samples were both lower. Notably, some sequences presented a high proportion in active samples and fatal/severe samples, while showed little proportion in recovered samples and mild/moderate samples, <italic>e.g</italic> CASSIEGQLSTDTQYF, CASSFGVAGGIYSPLHF, CASRLGLAGGNEQFF, and CASQGLVDENEQFF. In addition, we also found that the proportion of CSVESTALAAYNEQFF and CSVRAGTGGTEAFF presented little in active samples and fatal/severe samples but presented a high proportion in recovered samples and mild/moderate samples. That indicated that the high-abundance clonotypes may be associated with the severity degree and outcomes in different patients.</p>
    </sec>
    <sec id="sec0060">
      <label>3.3</label>
      <title>Construction of a classifier to identify TCR CDR3 with their recognizing SARS-CoV-2 epitopes</title>
      <p id="p0120">Those experimentally-verified recognition pairs between SARS-CoV-2 epitopes and TCR CDR3 sequences were downloaded from IEDB as positive pairs <xref rid="bib22" ref-type="bibr">[22]</xref>. To obtain negative pairs, those TCR CDR3 sequences derived from seven tumors and EVB were collected from IEDB and TCRdb <xref rid="bib24" ref-type="bibr">[24]</xref>, and randomly paired with those SARS-CoV-2 epitopes of the positive pairs. Subsequently, the positive pairs and the negative pairs were merged and filtered, a total of 50,949 pairs were obtained, and then randomly sampled them as training dataset and test dataset according to the ratio of 8:2 for model construction.</p>
      <p id="p0125">Based on the training dataset and test dataset above, a deep learning convolution neural network model, named CoV2-TCR, was constructed (<xref rid="sec0095" ref-type="sec">Fig. S1</xref>). Those epitope-CDR3 pairs were first encoded by using one-hot and zero-padded into a feature matrix, and then two 1D convolutional layers were applied for batch normalization. Next, a max pooling layer with pooling kernel size of 2 was followed to reduce the feature dimension and avoid overfitting. Three fully connected layers with an ReLU activation function followed the flattened layer, and then a dropout layer with probabilities of 0.3 was added for randomly discarding variables. Eventually, an output layer with two variables and the Softmax activation function was adopted to represent the final statistical classification score. Here, the predictive score of greater than 0.95 was treated as threshold of valid recognition between TCR CDR3 and SARS-CoV-2 epitopes. Consequently, we observed that the stable accuracy both converged in training dataset and test dataset, and the AUC reached 0.963 in the test dataset (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>a).<fig id="fig0015"><label>Fig. 3</label><caption><p>Performance of model CoV2-TCR specifically recognized to SARS-CoV2 epitopes. (a, b) The ROC curve of model CoV2-TCR in test dataset (a) and in independent validation dataset (b), respectively. (c) The ROC curves of model CoV2-TCR, imRex, ERGO-LSTM, and ERGO-AE in independent validation dataset.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p>
      <p id="p0130">Furthermore, to verify the performance of the model CoV2-TCR, an independent validation dataset was prepared and applied. We downloaded those TCRβ CDR3 and their recognizing SARS-CoV-2 epitopes from VDJdb <xref rid="bib23" ref-type="bibr">[23]</xref>. After excluding those pairs duplicated with positive pairs downloaded from IEDB, we treated the rest as positive pairs of the validation dataset. To produce negative pairs of the validation dataset, those TCR CDR3 derived from healthy people or induced by HIV were randomly paired with SARS-CoV-2 epitopes. Then, the positive pairs and negative pairs were merged and considered as an independent validation dataset. Here, the AUC of our model CoV2-TCR achieved at 0.967 in this independent validation dataset (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>b), indicating that model CoV2-TCR was an excellent classifier to probe the specific recognition between TCR CDR3 and SARS-CoV-2 epitopes.</p>
      <p id="p0135">Further, we compared the CoV2-TCR with other similar models, <italic>i.e.</italic> imRex <xref rid="bib32" ref-type="bibr">[32]</xref> and ERGO <xref rid="bib33" ref-type="bibr">[33]</xref>. By contrast, the imRex represents the interaction between epitopes and TCR CDR3 by combining amino-acid physicochemical properties and BLOSUM matrices, which are then used as inputs to construct convolutional neural network model. The ERGO was trained with two models, <italic>i.e.</italic> ERGO-AE and ERGO-LSTM, by using autoencoder (AE) and long short-term memory (LSTM), respectively. Based on the independent validation dataset, we found that the CoV2-TCR outperformed imRex, ERGO-LSTM, and ERGO-AE with a higher AUC (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>c), indicating that our model had better performance on predicting TCR CDR3 and their recognizing epitopes from SARS-CoV-2.</p>
    </sec>
    <sec id="sec0065">
      <label>3.4</label>
      <title>Identification of TCR CDR3 binding to SARS-CoV-2 antigen epitopes based on model CoV2-TCR</title>
      <p id="p0140">To classify those TCR CDR3 induced by SARS-CoV-2 epitopes from those clonotypes from COVID-19 samples, the model CoV2-TCR was applied for subsequent analysis. In a prior study <xref rid="bib34" ref-type="bibr">[34]</xref>, according to the amino-acid sequences of the four main proteins from SARS-COV-2, <italic>i.e.</italic> spike glycoprotein (S), membrane protein (M), envelop protein (E), and nucleocapsid protein (N), we screened 28 predicted MHC-I antigen peptides with the length of (8−11)-mer by performing a series of bioinformatics tools. Subsequently, based on those 380,305 unique clonotypes from COVID-19 patients but not from HD, including 37,562 High-abundance, 236,182 Low-abundance, 106,561 Rare clonotypes, the model CoV2-TCR was used to identify those TCR CDR3 that can specifically recognize these 28 predicted epitopes (<xref rid="sec0095" ref-type="sec">Table S1</xref>). As shown in <xref rid="tbl0005" ref-type="table">Table 1</xref>, we individually enumerated the 28 antigens and the number of TCR CDR3 sequences recognized, from 11 to 244,792, indicating a huge difference in T cell immune recognition to epitopes. Further, based on the clonal degree as described above, those TCR CDR3 sequences recognized to each epitope were separately divided into three groups (<italic>i.e.</italic> High-abundance, Low-abundance, Rare clonotypes). In those TCR CDR3 recognizing each epitope, we counted respectively their proportions in the total High-abundance, Low-abundance, and Rare clonotypes, and found that more TCR CDR3 did belong to Low-abundance clonotypes, but the proportions of High-abundance, Low-abundance, Rare clonotypes were close.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Those TCR CDR3 recognizing the 28 predicted MHC-I peptides from SARS-CoV-2.</p></caption><alt-text id="at0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>Protein</bold></th><th><bold>Position</bold></th><th><bold>Peptide</bold></th><th><bold>Length</bold></th><th><bold>TCR CDR3</bold><break/><bold>[score&gt; 0.95]</bold></th><th><bold>High-abundance</bold><break/><bold>(%)</bold></th><th><bold>Low-abundance</bold><break/><bold>(%)</bold></th><th><bold>Rare</bold><break/><bold>(%)</bold></th><th><bold>TCR CDR3 [top 1]</bold></th></tr></thead><tbody><tr><td>1</td><td>Envelop</td><td>E<sub>19–26</sub></td><td>LFLAFVVF</td><td>8</td><td>11</td><td>0 (0)</td><td>6 (0.003)</td><td>5 (0.005)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>2</td><td>Envelop</td><td>E<sub>20–27</sub></td><td>FLAFVVFL</td><td>8</td><td>222</td><td>18 (0.05)</td><td>129 (0.06)</td><td>75 (0.07)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>3</td><td>Envelop</td><td>E<sub>29–37</sub></td><td>VTLAILTAL</td><td>9</td><td>265</td><td>75 (0.20)</td><td>102 (0.04)</td><td>88 (0.08)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>4</td><td>Envelop</td><td>E<sub>29–38</sub></td><td>VTLAILTALR</td><td>10</td><td>7021</td><td>1239 (3.30)</td><td>3629 (1.54)</td><td>2153 (2.02)</td><td>CSVLSSNTGELFF</td></tr><tr><td>5</td><td>Envelop</td><td>E<sub>30–37</sub></td><td>TLAILTAL</td><td>8</td><td>276</td><td>49 (0.13)</td><td>145 (0.06)</td><td>82 (0.08)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>6</td><td>Membrane</td><td>M<sub>134–143</sub></td><td>LESELVIGAV</td><td>10</td><td>1590</td><td>130 (0.35)</td><td>968 (0.41)</td><td>492 (0.46)</td><td>CASSQEPPELAGWAGELFF</td></tr><tr><td>7</td><td>Membrane</td><td>M<sub>134–144</sub></td><td>LESELVIGAVI</td><td>11</td><td>3932</td><td>356 (0.95)</td><td>2314 (0.98)</td><td>1262 (1.19)</td><td>CASSQEPPELAGWAGELFF</td></tr><tr><td>8</td><td>Membrane</td><td>M<sub>135–144</sub></td><td>ESELVIGAVI</td><td>10</td><td>20,387</td><td>2113 (5.63)</td><td>12,561 (5.32)</td><td>5713 (5.36)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>9</td><td>Membrane</td><td>M<sub>136–146</sub></td><td>SELVIGAVILR</td><td>11</td><td>64,488</td><td>5696 (15.17)</td><td>40,879 (17.31)</td><td>17,913 (16.82)</td><td>CASSPQPNYRVWDTDTQYF</td></tr><tr><td>10</td><td>Membrane</td><td>M<sub>19–28</sub></td><td>QWNLVIGFLF</td><td>10</td><td>25,960</td><td>2608 (6.94)</td><td>16,204 (6.86)</td><td>7148 (6.71)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>11</td><td>Membrane</td><td>M<sub>4–14</sub></td><td>SNGTITVEELK</td><td>11</td><td>975</td><td>114 (0.30)</td><td>573 (0.24)</td><td>288 (0.27)</td><td>CSVEFRPPYGYTFGSGTSSYNEQFF</td></tr><tr><td>12</td><td>Membrane</td><td>M<sub>73–82</sub></td><td>INWITGGIAI</td><td>10</td><td>51,034</td><td>5201 (13.85)</td><td>31,568 (13.37)</td><td>14,265 (13.39)</td><td>CSVEVRWEGALYEQYF</td></tr><tr><td>13</td><td>Membrane</td><td>M<sub>76–84</sub></td><td>ITGGIAIAM</td><td>9</td><td>1877</td><td>144 (0.38)</td><td>1224 (0.52)</td><td>509 (0.48)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>14</td><td>Nucleocapsid</td><td>N<sub>10–17</sub></td><td>RNAPRITF</td><td>8</td><td>994</td><td>65 (0.17)</td><td>611 (0.26)</td><td>318 (0.30)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>15</td><td>Nucleocapsid</td><td>N<sub>111–121</sub></td><td>YYLGTGPEAGL</td><td>11</td><td>204,512</td><td>19,865 (52.89)</td><td>131,190 (55.55)</td><td>53,457 (50.19)</td><td>CSLMRGALYNEQFF</td></tr><tr><td>16</td><td>Nucleocapsid</td><td>N<sub>360–369</sub></td><td>YKTFPPTEPK</td><td>10</td><td>40,796</td><td>4066 (10.83)</td><td>24,637 (10.43)</td><td>12,093 (11.35)</td><td>CSLMRGALYNEQFF</td></tr><tr><td>17</td><td>Nucleocapsid</td><td>N<sub>9–17</sub></td><td>QRNAPRITF</td><td>9</td><td>467</td><td>39 (0.10)</td><td>265 (0.11)</td><td>163 (0.15)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>18</td><td>Spike</td><td>S<sub>1215–1224</sub></td><td>YIWLGFIAGL</td><td>10</td><td>17,270</td><td>1817 (4.84)</td><td>10,795 (4.57)</td><td>4658 (4.37)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>19</td><td>Spike</td><td>S<sub>1220–1230</sub></td><td>FIAGLIAIVMV</td><td>11</td><td>244,792</td><td>24,980 (66.51)</td><td>154,075 (65.24)</td><td>65,737 (61.71)</td><td>CSVVPSSPYNEQFF</td></tr><tr><td>20</td><td>Spike</td><td>S<sub>232–241</sub></td><td>GINITRFQTL</td><td>10</td><td>2078</td><td>277 (0.74)</td><td>1179 (0.50)</td><td>622 (0.58)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>21</td><td>Spike</td><td>S<sub>55–65</sub></td><td>FLPFFSNVTWF</td><td>11</td><td>740</td><td>46 (0.12)</td><td>460 (0.20)</td><td>234 (0.22)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>22</td><td>Spike</td><td>S<sub>62–70</sub></td><td>VTWFHAIHV</td><td>9</td><td>261</td><td>36 (0.10)</td><td>133 (0.06)</td><td>92 (0.09)</td><td>CSVEFRPPYGYTFGSGTSSYNEQFF</td></tr><tr><td>23</td><td>Spike</td><td>S<sub>627–636</sub></td><td>DQLTPTWRVY</td><td>10</td><td>9771</td><td>1023 (2.72)</td><td>5780 (2.45)</td><td>2968 (2.79)</td><td>CAWSPSWGDSRRNTEAFF</td></tr><tr><td>24</td><td>Spike</td><td>S<sub>628–636</sub></td><td>QLTPTWRVY</td><td>9</td><td>382</td><td>56 (0.15)</td><td>197 (0.08)</td><td>129 (0.12)</td><td>CSLMRGALYNEQFF</td></tr><tr><td>25</td><td>Spike</td><td>S<sub>825–835</sub></td><td>KVTLADAGFIK</td><td>11</td><td>10,070</td><td>1114 (2.97)</td><td>5900 (2.50)</td><td>3056 (2.87)</td><td>CSVEDLGQGLEINTEAFF</td></tr><tr><td>26</td><td>Spike</td><td>S<sub>826–835</sub></td><td>VTLADAGFIK</td><td>10</td><td>3344</td><td>407 (1.08)</td><td>2060 (0.87)</td><td>877 (0.82)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>27</td><td>Spike</td><td>S<sub>827–835</sub></td><td>TLADAGFIK</td><td>9</td><td>1449</td><td>270 (0.72)</td><td>778 (0.33)</td><td>401 (0.38)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>28</td><td>Spike</td><td>S<sub>876–884</sub></td><td>ALLAGTITS</td><td>9</td><td>2893</td><td>442 (1.18)</td><td>1507 (0.64)</td><td>944 (0.89)</td><td>CSVSLLNNWELTEAFF</td></tr></tbody></table></table-wrap></p>
      <p id="p0145">Besides, based on the four main proteins in SARS-CoV-2 and those amino-acid mutation site(s) of the seven SARS-CoV-2 variants (<italic>i.e.</italic> alpha, beta, delta, gamma, lambda, mu, omicron), we screened 22 predicted immunogenic peptides with %rank of less than 0.5 and IEDB immunogenicity score of greater than 0.15 (<xref rid="tbl0010" ref-type="table">Table 2</xref>). Similarly, the CoV2-TCR model was applied to identify those TCR CDR3 that can recognize specifically these selected peptides (<xref rid="sec0095" ref-type="sec">Table S2</xref>). Consistently, indeed, these peptides all can bind to some TCR CDR3 in those unshared clonotypes from COVID-19 patients, although the number of TCR CDR3 still presented a huge difference, ranging from 1 to 80,772. Also, for those TCR CDR3 recognizing each peptide, the proportions of High-abundance, Low-abundance, Rare clonotypes were still close (<xref rid="tbl0010" ref-type="table">Table 2</xref>). That denoted some immunogenic peptides induced adaptive immune response, leading to uniform T-cell expansion of High-abundance, Low-abundance, Rare clonotypes. In addition, those recognizing TCR CDR3 were compared with those downloaded from IEDB and VDJdb. We found that 16 peptides, of which TCR CDR3 recognizing sequences did overlap with those from the two databases (<italic>i.e.</italic> IEDB, VDJdb), although the peptides from SARS-CoV-2 variants may be completely different from those from positive pairs (<xref rid="sec0095" ref-type="sec">Table S3</xref>).<table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Those TCR CDR3 recognizing the 22 predicted immunogenic peptides from seven SARS-CoV-2 variants.</p></caption><alt-text id="at0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>Ancestry</bold></th><th><bold>Gene</bold></th><th><bold>Variant</bold></th><th><bold>Position</bold></th><th><bold>peptide</bold></th><th><bold>Rank% [0–0.5]</bold></th><th><bold>Immunogen</bold><break/><bold>[score&gt; 0.15]</bold></th><th><bold>TCR CDR3</bold><break/><bold>[score&gt; 0.95]</bold></th><th><bold>High-abundance</bold><break/><bold>(%)</bold></th><th><bold>Low-abundance</bold><break/><bold>(%)</bold></th><th><bold>Rare</bold><break/><bold>(%)</bold></th><th><bold>TCR CDR3 [top1]</bold></th></tr></thead><tbody><tr><td>1</td><td>Alpha</td><td>S</td><td>VY143–144 V</td><td>136–144</td><td>CNDPFLGVY</td><td align="char">0.27</td><td align="char">0.152</td><td>72</td><td>6 (0.02)</td><td>43 (0.02)</td><td>23 (0.02)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>2</td><td>Alpha</td><td>S</td><td>D1118H</td><td>1111–1121</td><td>EPQIITTDNTF</td><td align="char">0.483</td><td align="char">0.340</td><td>20,492</td><td>2110 (5.62)</td><td>12,708 (5.38)</td><td>5674 (5.33)</td><td>CSLMRGALYNEQFF</td></tr><tr><td>3</td><td>Alpha</td><td>S</td><td>VY143–144 V</td><td>135–144</td><td>FCNDPFLGVY</td><td align="char">0.26</td><td align="char">0.166</td><td>25,331</td><td>2568 (6.84)</td><td>15,355 (6.50)</td><td>7408 (6.96)</td><td>CSLMRGALYNEQFF</td></tr><tr><td>4</td><td>Alpha</td><td>S</td><td>T716I</td><td>714–722</td><td>IPINFTISV</td><td align="char">0.32</td><td align="char">0.203</td><td>96</td><td>9 (0.02)</td><td>63 (0.03)</td><td>24 (0.02)</td><td>CSVEFRPPYGYTFGSGTSSYNEQFF</td></tr><tr><td>5</td><td>Beta</td><td>S</td><td>TLLA240–243 T</td><td>233–241</td><td>INITRFQTL</td><td align="char">0.05</td><td align="char">0.168</td><td>59</td><td>11 (0.03)</td><td>20 (0.008)</td><td>28 (0.03)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>6</td><td>Beta/Gamma/Omicron</td><td>S</td><td>K417N</td><td>414–423</td><td>QTGNIADYNY</td><td align="char">0.26</td><td align="char">0.186</td><td>573</td><td>62 (0.17)</td><td>322 (0.14)</td><td>189 (0.18)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>7</td><td>Delta</td><td>S</td><td>G142D</td><td>136–145</td><td>CNDPFLDVYY</td><td align="char">0.444</td><td align="char">0.153</td><td>230</td><td>24 (0.06)</td><td>128 (0.05)</td><td>78 (0.07)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>8</td><td>Delta</td><td>S</td><td>G142D</td><td>135–144</td><td>FCNDPFLDVY</td><td align="char">0.249</td><td align="char">0.156</td><td>46,978</td><td>5338 (14.21)</td><td>28,156 (11.92)</td><td>13,484 (12.66)</td><td>CSVRRGNTGELFF</td></tr><tr><td>9</td><td>Gamma</td><td>S</td><td>K417T</td><td>415–424</td><td>TGTIADYNYK</td><td align="char">0.421</td><td align="char">0.195</td><td>3376</td><td>414 (1.10)</td><td>2067 (0.88)</td><td>895 (0.84)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>10</td><td>Mu</td><td>S</td><td>V143VT</td><td>136–145</td><td>CNDPFLGVTY</td><td align="char">0.452</td><td align="char">0.187</td><td>1399</td><td>141 (0.38)</td><td>833 (0.35)</td><td>425 (0.40)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>11</td><td>Mu</td><td>S</td><td>V143VT</td><td>136–146</td><td>CNDPFLGVTYY</td><td align="char">0.434</td><td align="char">0.202</td><td>1398</td><td>183 (0.49)</td><td>766 (0.32)</td><td>449 (0.42)</td><td>CSVEFRPPYGYTFGSGTSSYNEQFF</td></tr><tr><td>12</td><td>Mu/Omicron</td><td>S</td><td>T95I</td><td>89–97</td><td>GVYFASIEK</td><td align="char">0.014</td><td align="char">0.170</td><td>764</td><td>62 (0.17)</td><td>492 (0.21)</td><td>210 (0.20)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>13</td><td>Mu</td><td>S</td><td>V143VT</td><td>137–146</td><td>NDPFLGVTYY</td><td align="char">0.161</td><td align="char">0.206</td><td>95</td><td>11 (0.03)</td><td>56 (0.02)</td><td>28 (0.03)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>14</td><td>Omicron</td><td>S</td><td>G339D</td><td>339–347</td><td>DEVFNATRF</td><td align="char">0.206</td><td align="char">0.225</td><td>1</td><td>0 (0)</td><td>0 (0)</td><td>1 (0.001)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>15</td><td>Omicron</td><td>M</td><td>Q19E</td><td>18–26</td><td>EEWNLVIGF</td><td align="char">0.041</td><td align="char">0.226</td><td>6481</td><td>537 (1.43)</td><td>3968 (1.68)</td><td>1976 (1.86)</td><td>CASSYLGPSNTGELFF</td></tr><tr><td>16</td><td>Omicron</td><td>M</td><td>Q19E</td><td>18–28</td><td>EEWNLVIGFLF</td><td align="char">0.358</td><td align="char">0.349</td><td>80,772</td><td>7241 (19.28)</td><td>50,959 (21.58)</td><td>22,572 (21.19)</td><td>CASSQDAGPDSLFDTRELFF</td></tr><tr><td>17</td><td>Omicron</td><td>E</td><td>T9I</td><td>4–12</td><td>FVSEEIGTL</td><td align="char">0.356</td><td align="char">0.321</td><td>1043</td><td>101 (0.27)</td><td>661 (0.28)</td><td>281 (0.26)</td><td>CASTNQTSMYLCASSLASGNYEQYF</td></tr><tr><td>18</td><td>Omicron</td><td>M</td><td>Q19E</td><td>15–23</td><td>KLLEEWNLV</td><td align="char">0.046</td><td align="char">0.391</td><td>516</td><td>60 (0.16)</td><td>292 (0.12)</td><td>164 (0.15)</td><td>CASSLQWGDSVSTEAFF</td></tr><tr><td>19</td><td>Omicron</td><td>M</td><td>A63T</td><td>56–64</td><td>LLWPVTLTC</td><td align="char">0.453</td><td align="char">0.151</td><td>14,949</td><td>1574 (4.19)</td><td>8989 (3.81)</td><td>4386 (4.12)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>20</td><td>Omicron</td><td>S</td><td>S375F</td><td>370–378</td><td>NSASFFTFK</td><td align="char">0.07</td><td align="char">0.172</td><td>464</td><td>36 (0.10)</td><td>260 (0.11)</td><td>168 (0.16)</td><td>CASSIEAWLNIQYFGAGTRLGELFF</td></tr><tr><td>21</td><td>Omicron</td><td>E</td><td>T9I</td><td>6–14</td><td>SEEIGTLIV</td><td align="char">0.433</td><td align="char">0.304</td><td>1326</td><td>183 (0.49)</td><td>671 (0.28)</td><td>472 (0.44)</td><td>CASSSQTVIPRARANYGYTF</td></tr><tr><td>22</td><td>Omicron</td><td>S</td><td>A67V</td><td>62–70</td><td>VTWFHVIHV</td><td align="char">0.473</td><td align="char">0.391</td><td>2946</td><td>339 (0.90)</td><td>1692 (0.72)</td><td>915 (0.86)</td><td>CSVEFRPPYGYTFGSGTSSYNEQFF</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="sec0070">
      <label>3.5</label>
      <title>A web-based tool to identify TCR CDR3 recognizing SARS-CoV-2 peptides</title>
      <p id="p0150">Given the results of the investigation above, the model CoV2-TCR was implemented in a user-friendly web server (http://www.biostatistics.online/CoV2-TCR/#/). In addition, the four main proteins in SARS-CoV-2, <italic>i.e.</italic> spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N), have been integrated as well. As we have known, based on the amino-acid sequences of these proteins, there were four probable mutation types, including single amino acid variation (SAAV), insertion and deletion of amino acids (InDelAA), insertion of amino acids (InAA), deletion of amino acids (DelAA) <xref rid="bib35" ref-type="bibr">[35]</xref>.</p>
      <p id="p0155">In the process of operating the webserver, before submitting a task, users need to select a mutated protein and its mutation type, and input mutation site(s) and amino acid change. Then, nine peptides containing mutation site(s) (9-mer) will be respectively extracted for subsequent prediction by CoV2-TCR. Those pairs between peptide and TCR CDR3 with predictive score of greater than 0.95 will be recorded in an Excel file and sent to the user as an email. The output file will consisted of five columns, including SARS-CoV-2 Epitope, TCR CDR3, CDR3 clone degree, Predictive score, and Interaction.</p>
      <p id="p0160">During the infection process of SARS-CoV-2, the spike protein plays a crucial role in interacting with the human angiotensin-converting enzyme 2 (hACE2) receptor <xref rid="bib36" ref-type="bibr">[36]</xref>. Singh et al <xref rid="bib37" ref-type="bibr">[37]</xref>. identified the highly flexible region in the receptor binding domain of SARS-CoV-2, starting from residue 475–485 of spike protein. Particularly, the two amino-acid exchanges, <italic>i.e.</italic> S477G and S477N, were reported to strengthen the binding of the SARS-COV-2 spike with the hACE2 receptor <xref rid="bib37" ref-type="bibr">[37]</xref>. Subsequently, here as a case, the two mutations were separately inputted into the CoV2-TCR, and those TCR CDR3 recognizing those peptides containing mutation site was identified (<xref rid="sec0095" ref-type="sec">Tables S4</xref> and <xref rid="sec0095" ref-type="sec">S5</xref>). The peptides TEIYQAG(G)T and TEIYQAG(N)T were recognized respectively by the most TCR CDR3, suggesting their potential as candidate vaccine peptides.</p>
    </sec>
  </sec>
  <sec id="sec0075">
    <label>4</label>
    <title>Discussion</title>
    <p id="p0165">In this study, on the basis of trancriptomic files from peripheral blood of COVID-19 patients and HD subjects, the TCR immune repertoires were investigated and analyzed. Meanwhile, we found the severity degree of the COVID-19 patients was negatively correlated with the diversity of TCR repertoires, and was positively correlated to their clonality. Furthermore, when we assigned those clonotypes into High-abundance, Low-abundance, Rare groups, the proportion of high-abundance clonotypes was found to be associated with the severity degree of COVID-19 patients. Indeed, the more cells infected with SARS-CoV-2 in host, the more severe the disease became <xref rid="bib38" ref-type="bibr">[38]</xref>. Sustained stimulation by antigen epitopes from SARS-CoV-2 would cause biased cloning expansion, leading to a bias T cell immune repertoire with low diversity.</p>
    <p id="p0170">Furthermore, a clear difference was discovered when the proportions of the top 20 TCR CDR3 were explored in COVID-19 patients. Interestingly, we observed that two sequences, <italic>i.e.</italic> CSVESTALAAYNEQFF and CSVRAGTGGTEAFF presented little in active samples and fatal/severe samples, but high proportion in recovered samples and mild/moderate samples. That indicated the severity degree of disease may be related to the amplified TCR CDR3 sequences. In addition, previous reports showed that those unexposed-unvaccinated individuals carried a significant fraction of circulating CD8 + T cells reactive to epitopes from SARS-CoV-2. These CD8 + T cells may belong to memory and naive T cells derived from other coronavirus infections <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>. The public shared T cells repertoire in COVID-19 patients may contain an unexpected fraction of TCR clonotypes that can react to different epitopes from SARS-CoV-2 variants. Thus, we believed that, among the TCR CDR3 in COVID-19 patients, there existed some TCR CDR3 that can recognize those mutated epitopes from any SARS-CoV-2 variants.</p>
    <p id="p0175">To investigate the TCR repertoire of COVID-19 patients and their recognized epitopes from SARS-CoV-2 or its variants, a precise model CoV2-TCR was constructed and outperformed the similar models, <italic>i.e.</italic> imRex <xref rid="bib32" ref-type="bibr">[32]</xref>, ERGO-LSTM <xref rid="bib33" ref-type="bibr">[33]</xref>, and ERGO-AE <xref rid="bib33" ref-type="bibr">[33]</xref>. In addition, by comparison with the TCRmatch <xref rid="bib40" ref-type="bibr">[40]</xref> and TCRdist <xref rid="bib41" ref-type="bibr">[41]</xref> constructed by the similarity-based or distance-based approaches, the CoV2-TCR was established by convolution neural network, whose advantage lies in its capacity of feature extraction. NetTCR-2.0 was trained to predict interactions between TCRs and their cognate HLA-A* 02:01-restricted peptides <xref rid="bib42" ref-type="bibr">[42]</xref>. Due to the small number of training peptides, the tool can only be applied to the limited peptides included in the training data. The CoV2-TCR we proposed in this study provided a generic strategy that can specifically recognize MHC-I epitopes from SARS-CoV-2 or its variants. We believe that our method could be extended to some similar protein-binding situations, helping to guide the selection of candidate vaccine polypeptides and immunotherapeutic TCR-T.</p>
    <p id="p0180">When the CoV2-TCR was used to explore those TCR CDR3 recognizing those predicted epitopes from SARS-CoV-2 or its variants, the number of TCR CDR3 was found to exhibit a huge variability. This is why immunogenic epitopes need to be screened for use as peptide vaccines. Indeed, the CoV2-TCR could provide preliminary screening, in which those epitopes from SARS-CoV-2 variants recognized by most TCR CDR3 may be selected as candidate antigen peptides for vaccine design. In addition, in those TCR CDR3 recognizing each epitope, we observed the close proportions of High-abundance, Low-abundance, Rare clonotypes in the total population, suggesting that those immunogenic peptides may cause uniform immune response in host.</p>
    <p id="p0185">In conclusion, this study investigated the TCR repertoire of SARS-CoV-2 infected patients, and those TCR CDR3 existed in COVID-19 patients were found to recognize epitopes from mutation(s) of SARS-CoV-2 variants. Notably, we established an easy-to-use web server for screening TCR CDR3 sequences that can recognize a specific SARS-CoV-2 mutated peptide, which would be helpful to identify candidate antigen peptides responding to SARS-CoV-2 variants.</p>
  </sec>
  <sec id="sec0080">
    <title>Funding</title>
    <p id="p0190">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (31900102, 31870829), <funding-source id="gs2">Shanghai Municipal Health Commission Collaborative Innovation Cluster Project</funding-source> (2019CXJQ02), and <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004735</institution-id><institution>Natural Science Foundation of Hunan Province</institution></institution-wrap></funding-source> (2021JJ40995).</p>
  </sec>
  <sec id="sec0085">
    <title>CRediT authorship contribution statement</title>
    <p id="p0195"><bold>Xingxing Jian</bold>: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review &amp; editing. <bold>Yu Zhang</bold>: Investigation, Software, Methodology. <bold>Jingjing Zhao</bold>: Conceptualization, Investigation, Methodology. <bold>Zhuoming Zhao</bold>: Investigation, Discussion. <bold>Manman Lu</bold>: Investigation, Discussion. <bold>Lu Xie</bold>: Conceptualization, Investigation, Supervision, Writing – review &amp; editing.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0200">All authors declare no competing interests.</p>
  </sec>
</body>
<back>
  <ref-list id="bibliog0005">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sbref1">
        <person-group person-group-type="author">
          <name>
            <surname>Agerer</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Koblischke</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Gudipati</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Montano-Gutierrez</surname>
            <given-names>L.F.</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Popa</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses</article-title>
        <source>Sci Immunol</source>
        <volume>6</volume>
        <issue>57</issue>
        <year>2021</year>
        <fpage>eabg6461</fpage>
        <pub-id pub-id-type="pmid">33664060</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sbref2">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination</article-title>
        <source>Emerg Microbes Infect</source>
        <volume>12</volume>
        <issue>1</issue>
        <year>2023</year>
        <fpage>2151381</fpage>
        <pub-id pub-id-type="pmid">36444724</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sbref3">
        <person-group person-group-type="author">
          <name>
            <surname>Dhama</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Nainu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Frediansyah</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Yatoo</surname>
            <given-names>M.I.</given-names>
          </name>
          <name>
            <surname>Mohapatra</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Chakraborty</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies</article-title>
        <source>J Infect Public Health</source>
        <volume>16</volume>
        <issue>1</issue>
        <year>2023</year>
        <fpage>4</fpage>
        <lpage>14</lpage>
        <pub-id pub-id-type="pmid">36446204</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sbref4">
        <person-group person-group-type="author">
          <name>
            <surname>Tang-Huau</surname>
            <given-names>T.L.</given-names>
          </name>
          <name>
            <surname>Gueguen</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Goudot</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Durand</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Segura</surname>
            <given-names>E.J.N.C.</given-names>
          </name>
        </person-group>
        <article-title>Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway</article-title>
        <source>Nat Commun 2018</source>
        <volume>9</volume>
        <issue>1</issue>
        <year>2018</year>
        <fpage>2570</fpage>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sbref5">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
        <source>Lancet</source>
        <volume>395</volume>
        <issue>10223</issue>
        <year>2020</year>
        <fpage>497</fpage>
        <lpage>506</lpage>
        <pub-id pub-id-type="pmid">31986264</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sbref6">
        <person-group person-group-type="author">
          <name>
            <surname>Dash</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Fiore-Gartland</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Hertz</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.C.</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Souquette</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Quantifiable predictive features define epitope-specific T cell receptor repertoires</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <issue>7661</issue>
        <year>2017</year>
        <fpage>89</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="pmid">28636592</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sbref7">
        <person-group person-group-type="author">
          <name>
            <surname>Le Bert</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>A.T.</given-names>
          </name>
          <name>
            <surname>Kunasegaran</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Tham</surname>
            <given-names>C.Y.L.</given-names>
          </name>
          <name>
            <surname>Hafezi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chia</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Chng</surname>
            <given-names>M.H.Y.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Linster</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>
        <source>Nature</source>
        <volume>584</volume>
        <issue>7821</issue>
        <year>2020</year>
        <fpage>457</fpage>
        <lpage>462</lpage>
        <pub-id pub-id-type="pmid">32668444</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sbref8">
        <person-group person-group-type="author">
          <name>
            <surname>Mathew</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Giles</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Baxter</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Oldridge</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Greenplate</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>
        <source>Science</source>
        <volume>369</volume>
        <issue>6508</issue>
        <year>2020</year>
        <fpage>eabc8511</fpage>
        <pub-id pub-id-type="pmid">32669297</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sbref9">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ling</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Yi</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Viral and host factors related to the clinical outcome of COVID-19</article-title>
        <source>Nature</source>
        <volume>583</volume>
        <issue>7816</issue>
        <year>2020</year>
        <fpage>437</fpage>
        <lpage>440</lpage>
        <pub-id pub-id-type="pmid">32434211</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sbref10">
        <person-group person-group-type="author">
          <name>
            <surname>McMahan</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mercado</surname>
            <given-names>N.B.</given-names>
          </name>
          <name>
            <surname>Loos</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tostanoski</surname>
            <given-names>L.H.</given-names>
          </name>
          <name>
            <surname>Chandrashekar</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>
        <source>Nature</source>
        <volume>590</volume>
        <issue>7847</issue>
        <year>2021</year>
        <fpage>630</fpage>
        <lpage>634</lpage>
        <pub-id pub-id-type="pmid">33276369</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sbref11">
        <person-group person-group-type="author">
          <name>
            <surname>Hansen</surname>
            <given-names>S.G.</given-names>
          </name>
          <name>
            <surname>Ford</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Ventura</surname>
            <given-names>A.B.</given-names>
          </name>
          <name>
            <surname>Hughes</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Coyne-Johnson</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine</article-title>
        <source>Nature</source>
        <volume>473</volume>
        <issue>7348</issue>
        <year>2011</year>
        <fpage>523</fpage>
        <lpage>527</lpage>
        <pub-id pub-id-type="pmid">21562493</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sbref12">
        <person-group person-group-type="author">
          <name>
            <surname>Masopust</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Soerens</surname>
            <given-names>A.G.</given-names>
          </name>
        </person-group>
        <article-title>Tissue-resident T cells and other resident leukocytes</article-title>
        <source>Annu Rev Immunol</source>
        <volume>37</volume>
        <year>2019</year>
        <fpage>521</fpage>
        <lpage>546</lpage>
        <pub-id pub-id-type="pmid">30726153</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sbref13">
        <person-group person-group-type="author">
          <name>
            <surname>Grau-Exposito</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Sanchez-Gaona</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Massana</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Suppi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Astorga-Gamaza</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Perea</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Peripheral and lung resident memory T cell responses against SARS-CoV-2</article-title>
        <source>Nat Commun</source>
        <volume>12</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>3010</fpage>
        <pub-id pub-id-type="pmid">34021148</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sbref14">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China</article-title>
        <source>JAMA Intern Med</source>
        <volume>180</volume>
        <issue>7</issue>
        <year>2020</year>
        <fpage>934</fpage>
        <lpage>943</lpage>
        <pub-id pub-id-type="pmid">32167524</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sbref15">
        <person-group person-group-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Mentzer</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</article-title>
        <source>Nat Immunol</source>
        <volume>21</volume>
        <issue>11</issue>
        <year>2020</year>
        <fpage>1336</fpage>
        <lpage>1345</lpage>
        <pub-id pub-id-type="pmid">32887977</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sbref16">
        <person-group person-group-type="author">
          <name>
            <surname>Notarbartolo</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ranzani</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Bandera</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gruarin</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Bevilacqua</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Putignano</surname>
            <given-names>A.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients</article-title>
        <source>Sci Immunol</source>
        <volume>6</volume>
        <issue>62</issue>
        <year>2021</year>
        <fpage>eabg5021</fpage>
        <pub-id pub-id-type="pmid">34376481</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sbref17">
        <person-group person-group-type="author">
          <name>
            <surname>Grifoni</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Weiskopf</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Ramirez</surname>
            <given-names>S.I.</given-names>
          </name>
          <name>
            <surname>Mateus</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dan</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Moderbacher</surname>
            <given-names>C.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title>
        <source>Cell</source>
        <volume>181</volume>
        <issue>7</issue>
        <year>2020</year>
        <fpage>1489</fpage>
        <lpage>1501</lpage>
        <pub-id pub-id-type="pmid">32473127</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sbref18">
        <person-group person-group-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Loyal</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Frentsch</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wendisch</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Georg</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Kurth</surname>
            <given-names>F.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title>
        <source>Nature</source>
        <volume>587</volume>
        <issue>7833</issue>
        <year>2020</year>
        <fpage>270</fpage>
        <lpage>274</lpage>
        <pub-id pub-id-type="pmid">32726801</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sbref19">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>dbPepNeo2.0: A database for human tumor neoantigen peptides from mass spectrometry and TCR recognition</article-title>
        <source>Front Immunol</source>
        <volume>13</volume>
        <year>2022</year>
        <object-id pub-id-type="publisher-id">855976</object-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sbref20">
        <person-group person-group-type="author">
          <name>
            <surname>Schultheiss</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Paschold</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Simnica</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Mohme</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Willscher</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Wenserski</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease</article-title>
        <source>Immunity</source>
        <volume>53</volume>
        <issue>2</issue>
        <year>2020</year>
        <fpage>442</fpage>
        <lpage>455</lpage>
        <pub-id pub-id-type="pmid">32668194</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sbref21">
        <person-group person-group-type="author">
          <name>
            <surname>Bolotin</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Poslavsky</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Mitrophanov</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Shugay</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mamedov</surname>
            <given-names>I.Z.</given-names>
          </name>
          <name>
            <surname>Putintseva</surname>
            <given-names>E.V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MiXCR: software for comprehensive adaptive immunity profiling</article-title>
        <source>Nat Methods</source>
        <volume>12</volume>
        <issue>5</issue>
        <year>2015</year>
        <fpage>380</fpage>
        <lpage>381</lpage>
        <pub-id pub-id-type="pmid">25924071</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sbref22">
        <person-group person-group-type="author">
          <name>
            <surname>Vita</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Mahajan</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Overton</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Dhanda</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Martini</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Cantrell</surname>
            <given-names>J.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The immune epitope database (IEDB): 2018 update</article-title>
        <source>Nucleic Acids Res</source>
        <volume>47</volume>
        <issue>D1</issue>
        <year>2019</year>
        <fpage>D339</fpage>
        <lpage>D343</lpage>
        <pub-id pub-id-type="pmid">30357391</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sbref23">
        <person-group person-group-type="author">
          <name>
            <surname>Shugay</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bagaev</surname>
            <given-names>D.V.</given-names>
          </name>
          <name>
            <surname>Zvyagin</surname>
            <given-names>I.V.</given-names>
          </name>
          <name>
            <surname>Vroomans</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Crawford</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Dolton</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>VDJdb: a curated database of T-cell receptor sequences with known antigen specificity</article-title>
        <source>Nucleic Acids Res</source>
        <volume>46</volume>
        <issue>D1</issue>
        <year>2018</year>
        <fpage>D419</fpage>
        <lpage>D427</lpage>
        <pub-id pub-id-type="pmid">28977646</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sbref24">
        <person-group person-group-type="author">
          <name>
            <surname>Shomuradova</surname>
            <given-names>A.S.</given-names>
          </name>
          <name>
            <surname>Vagida</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Sheetikov</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Zornikova</surname>
            <given-names>K.V.</given-names>
          </name>
          <name>
            <surname>Kiryukhin</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Titov</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors</article-title>
        <source>Immunity</source>
        <volume>53</volume>
        <issue>6</issue>
        <year>2020</year>
        <fpage>1245</fpage>
        <lpage>1257</lpage>
        <comment>e5</comment>
        <pub-id pub-id-type="pmid">33326767</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sbref25">
        <person-group person-group-type="author">
          <name>
            <surname>Gong</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.P.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>L.N.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>B.X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An online coronavirus analysis platform from the National Genomics Data Center</article-title>
        <source>Zool Res</source>
        <volume>41</volume>
        <issue>6</issue>
        <year>2020</year>
        <fpage>705</fpage>
        <lpage>708</lpage>
        <pub-id pub-id-type="pmid">33045776</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sbref26">
        <person-group person-group-type="author">
          <name>
            <surname>Song</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The global landscape of SARS-CoV-2 genomes, variants, and haplotypes in 2019nCoVR</article-title>
        <source>Genom Prote Bioinf</source>
        <volume>18</volume>
        <issue>6</issue>
        <year>2020</year>
        <fpage>749</fpage>
        <lpage>759</lpage>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sbref27">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Duan</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Coronavirus GenBrowser for monitoring the transmission and evolution of SARS-CoV-2</article-title>
        <source>Brief Bioinform</source>
        <volume>23</volume>
        <issue>2</issue>
        <year>2022</year>
        <object-id pub-id-type="publisher-id">bbab583</object-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sbref28">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>W.M.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>L.N.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>Y.K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The 2019 novel coronavirus resource</article-title>
        <source>Yi Chuan</source>
        <volume>42</volume>
        <issue>2</issue>
        <year>2020</year>
        <fpage>212</fpage>
        <lpage>221</lpage>
        <pub-id pub-id-type="pmid">32102777</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sbref29">
        <person-group person-group-type="author">
          <name>
            <surname>Reynisson</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Alvarez</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Paul</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data</article-title>
        <source>Nucleic Acids Res</source>
        <volume>48</volume>
        <issue>W1</issue>
        <year>2020</year>
        <fpage>W449</fpage>
        <lpage>W454</lpage>
        <pub-id pub-id-type="pmid">32406916</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sbref30">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>B.V.</given-names>
          </name>
          <name>
            <surname>Connors</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Farber</surname>
            <given-names>D.L.</given-names>
          </name>
        </person-group>
        <article-title>Human T cell development, localization, and function throughout life</article-title>
        <source>Immunity</source>
        <volume>48</volume>
        <issue>2</issue>
        <year>2018</year>
        <fpage>202</fpage>
        <lpage>213</lpage>
        <pub-id pub-id-type="pmid">29466753</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sbref31">
        <person-group person-group-type="author">
          <name>
            <surname>Katayama</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yokota</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Akiyama</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>T.J.</given-names>
          </name>
        </person-group>
        <article-title>Machine learning approaches to TCR repertoire analysis</article-title>
        <source>Front Immunol</source>
        <volume>13</volume>
        <year>2022</year>
        <object-id pub-id-type="publisher-id">858057</object-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sbref32">
        <person-group person-group-type="author">
          <name>
            <surname>Moris</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>De Pauw</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Postovskaya</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gielis</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>De Neuter</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Bittremieux</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Current challenges for unseen-epitope TCR interaction prediction and a new perspective derived from image classification</article-title>
        <source>Brief Bioinform</source>
        <volume>22</volume>
        <issue>4</issue>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">bbaa318</object-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sbref33">
        <person-group person-group-type="author">
          <name>
            <surname>Springer</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Besser</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Tickotsky-Moskovitz</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Dvorkin</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Louzoun</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs</article-title>
        <source>Front Immunol</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>1803</fpage>
        <pub-id pub-id-type="pmid">32983088</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sbref34">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Bioinformatics prediction of candidate epitopes for peptide vaccines based on pathogen antigenic protein sequences</article-title>
        <source>Life Sci Res</source>
        <volume>25</volume>
        <issue>04</issue>
        <year>2021</year>
        <fpage>363</fpage>
        <lpage>371</lpage>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sbref35">
        <person-group person-group-type="author">
          <name>
            <surname>Jian</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma</article-title>
        <source>Mol Ther Nucleic Acids</source>
        <volume>29</volume>
        <year>2022</year>
        <fpage>285</fpage>
        <lpage>295</lpage>
        <pub-id pub-id-type="pmid">35950215</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sbref36">
        <person-group person-group-type="author">
          <name>
            <surname>Walls</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>Y.J.</given-names>
          </name>
          <name>
            <surname>Tortorici</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Wall</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>McGuire</surname>
            <given-names>A.T.</given-names>
          </name>
          <name>
            <surname>Veesler</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>
        <source>Cell</source>
        <volume>181</volume>
        <issue>2</issue>
        <year>2020</year>
        <fpage>281</fpage>
        <lpage>292</lpage>
        <comment>e6</comment>
        <pub-id pub-id-type="pmid">32155444</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sbref37">
        <person-group person-group-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Steinkellner</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Kochl</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Gruber</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Gruber</surname>
            <given-names>C.C.</given-names>
          </name>
        </person-group>
        <article-title>Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2</article-title>
        <source>Sci Rep</source>
        <volume>11</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>4320</fpage>
        <pub-id pub-id-type="pmid">33619331</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sbref38">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Pang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals</article-title>
        <source>Cell Disco</source>
        <volume>7</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>89</fpage>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sbref39">
        <person-group person-group-type="author">
          <name>
            <surname>Quiros-Fernandez</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Poorebrahim</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Fakhr</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Cid-Arregui</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naive CD8 T cells of unexposed individuals</article-title>
        <source>EBioMedicine</source>
        <volume>72</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">103610</object-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sbref40">
        <person-group person-group-type="author">
          <name>
            <surname>Chronister</surname>
            <given-names>W.D.</given-names>
          </name>
          <name>
            <surname>Crinklaw</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Mahajan</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Vita</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Kosaloglu-Yalcin</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TCRMatch: Predicting T-Cell receptor specificity based on sequence similarity to previously characterized receptors</article-title>
        <source>Front Immunol</source>
        <volume>12</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">640725</object-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sbref41">
        <person-group person-group-type="author">
          <name>
            <surname>Olson</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Schattgen</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>P.G.</given-names>
          </name>
          <name>
            <surname>Bradley</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Matsen</surname>
            <given-names>Iv, F.A.</given-names>
          </name>
        </person-group>
        <article-title>Comparing T cell receptor repertoires using optimal transport</article-title>
        <source>PLoS Comput Biol</source>
        <volume>18</volume>
        <issue>12</issue>
        <year>2022</year>
        <object-id pub-id-type="publisher-id">e1010681</object-id>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>42</label>
      <element-citation publication-type="journal" id="sbref42">
        <person-group person-group-type="author">
          <name>
            <surname>Montemurro</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Schuster</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Povlsen</surname>
            <given-names>H.R.</given-names>
          </name>
          <name>
            <surname>Bentzen</surname>
            <given-names>A.K.</given-names>
          </name>
          <name>
            <surname>Jurtz</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Chronister</surname>
            <given-names>W.D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCR alpha and beta sequence data</article-title>
        <source>Commun Biol</source>
        <volume>4</volume>
        <issue>1</issue>
        <year>2021</year>
        <fpage>1060</fpage>
        <pub-id pub-id-type="pmid">34508155</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="sec0095" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary material</title>
    <p id="p0215"><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material>.</p>
    <p id="p0220"><supplementary-material content-type="local-data" id="ec0010"><caption><p>Supplementary material</p></caption><media xlink:href="mmc2.xlsx"/></supplementary-material>.</p>
    <p id="p0225"><supplementary-material content-type="local-data" id="ec0015"><caption><p>Supplementary material</p></caption><media xlink:href="mmc3.xlsx"/></supplementary-material>.</p>
    <p id="p0230"><supplementary-material content-type="local-data" id="ec0020"><caption><p>Supplementary material</p></caption><media xlink:href="mmc4.xlsx"/></supplementary-material>.</p>
    <p id="p0235"><supplementary-material content-type="local-data" id="ec0025"><caption><p>Supplementary material</p></caption><media xlink:href="mmc5.xlsx"/></supplementary-material>.</p>
    <p id="p0240"><supplementary-material content-type="local-data" id="ec0030"><caption><p>Supplementary material</p></caption><media xlink:href="mmc6.xlsx"/></supplementary-material>.</p>
  </sec>
  <ack id="ack0005">
    <title>Acknowledgments</title>
    <p id="p0205">We appreciate the resources provided by the High Performance Computing Center of Central South University.</p>
  </ack>
  <fn-group>
    <fn id="sec0090" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0210">Supplementary data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2023.01.038" id="ir0005">doi:10.1016/j.csbj.2023.01.038</ext-link>.</p>
    </fn>
  </fn-group>
</back>
